anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Quality assurance - "clalit" health services will provide ongoing auditing and monitoring of the study. data checks will be also examined by "clalit health services". the investigators are obliged to enter all the data into logs provided upfront by the organisation. All the data obtained will be stored in an original folder intended for inspection and all encounters with volunteers will be documented in the computerized medical file of the volunteers. Standard operating procedures will be followed by the regulations expected by "clalit" health services and the Israeli ministry of health. After the first 10 volunteers of the study a reliability and validity statistical analysis will be made to assess the sample size estimated. Missing, unavailable, "non-reported" or uninterpretable data will be excluded from the final analysis.Data will be analyzed using the Statistical Package for the Social Sciences Version 15 (SPSS Inc., Chicago, IL, USA). Results of measurements of each test will be analyzed for mean, standard deviation (SD) and range. Categorical variables will be described percentiles/median. Changes of variables in the same subject will be analyzed using a paired T test for continuous variables and Mann-Whitney test for categorical variables. In addition, the correlations between variables will be calculated using ICC. P values smaller than 0.05 (p\<0.05) will be considered significant
FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
This study is designed to help understand the mechanism of action of ARP in major depressive disorder (MDD) augmentation. Subjects will undergo exposure to an existing antidepressant (Lexapro 10-20mg) for 10 weeks; subjects failing to completely respond to the monotherapy antidepressant treatment will receive augmentation with ARP for six weeks. Two placebo phases are included in which the subjects will receive one placebo along with the Lexapro for the first 6 weeks and a second placebo along with Lexapro for the next two weeks. A baseline brain imaging series (MRI and 2 PET/CT scans) will be obtained at week 10, prior to starting the aripiprazole, on subjects not responding to Lexapro. A second series of images will be obtained at the end of the six weeks of ARP augmentation. The neuroimaging will consist of fMRI, a raclopride PET scan, and a fluoro-dopa PET scan.

Ten normal control subjects will not receive any treatment. They will be age and gender matched to study subjects and undergo one set of scans (fMRI,raclopride and FOPA PET scans) to use as comparison group for quality control on a non-depressed population and not for data analysis.
PURPOSE:To obtain the titled powder having high fluidity and excellent dispersibility in water and containing vitamin E in high concentration, by using an emulsion of vitamin E which is an oily drug effective to habitual abortion, amyotrophy, cardiopathy, etc., and spray-drying the emulsion together with several specific kinds of additives. CONSTITUTION:The objective powder is produced by spray-drying a mixture of (A) vitamin E, (B) hydroxypropyl cellulose having low substitution degree or crystalline cellulose.carboxymethylcellulose sodium salt, (C) a pluronic or Tween-type surfactant and (D) silicic anhydride. The amounts of the hydroxypropyl cellulose having low substitution degree, the surfactant of the component C and the component D are preferably 0.6-1.2pts.wt., 0.05-1pt.wt. and 0.1-0.4pt.wt. per 1pt.wt. of vitamin E, respectively. Vitamin E exists in vegetable oils and fats such as wheat embryo oil and cottonseed oil.
PURPOSE:To prepare a stable liposome aqueous dispersion containing a hydroxy acid and an amino acid as stabilizers, and enabling to prevent the coloration of the products, the production of precipitates, the leakage of contents, etc. CONSTITUTION:The characteristic of this stabilized liposome aqueous dispersion comprises adding a hydroxy acid, preferably lactic acid, malic acid or tartaric acid, especially citric acid or its pharmacologically permissible salt, and an amino acid, preferably methionine, histidine, arginine, glutamic acid, aspartic acid or their pharmacologically permissible salts as stabilizers to a liposome aqueous solution containing york lecithin and/or soybean lecithin as liposome film-forming substances. 0.05-5 pts.wt. of the citric acid, 0.008-0.8 pt.wt. of methionine, 0.0006-0.3 pt.wt. of histidine, 0.02-4 pts.wt. of the arginine, or 0.015-3 pts.wt. of the glutamic acid or aspartic acid per pt.wt. of the film-forming substances are used.
The disclosure notably relates to a computer-implemented for parameterizing a statistical function. The statistical function is configured for performing prognosis on cancer patients. The parameterizing method comprises providing a dataset relative to a plurality of patients each having a cancer disease. The dataset includes, for each patient, input data of the statistical function. The input data comprise visual data from at least one histological image of a tumor slide of the patient. The input data also comprise genomic data from sequencing tumor tissue of the patient. The input data further comprise clinical data of the patient. The dataset also includes clinical endpoints of the patient with respect to evolution of the cancer disease. The parameterizing method further comprises parameterizing the statistical function based on the dataset. This forms an improved solution to perform prognosis on patients having a cancer disease.
As per previous recommendation the English version of Nottingham Extended Activities Of Daily Living Scale will be translated into Urdu and it will be culturally adapted. Nottingham Extended Activities Of Daily Living Scale will be given to eighty individuals of stroke population which were selected on the basis of convenience sampling and the criteria of inclusion and exclusion. Study will investigate both inter-observer and intra-observer reliability of Nottingham Extended Activities Of Daily Living Scale, Modified Barthel Index and Frenchay Activities Index; the 2 set of questionnaire designed will be given to the participants on the same day to be filled, by two observers. And with a gap of half an hour between distributions of first two forms questionnaires will be given for inter-observer assessment. And after a time period of one week a third assessment will be collected by the first observer (intra-observer assessment). Statistical Package of Social Sciences Version 24 will be used for data entry and analysis. Cronbach alpha value will be used for checking internal consistency and intra-class correlation coefficient will be used to analyze test retest reliability.
If you decide to participate in the study and are eligible, you will undergo a single \[11C\] acetate PET scan. This scan is designed to detect small amounts of your tumor that were not detected by the CT scan or the bone scan. On the day of the scan, you will fast for at least four hours prior to being given the tracer injection by vein. You will then be scanned in the PET scanner. The entire procedure will take approximately 2 hours.

The investigators would like to keep track of your medical condition after you have completed your scan. The investigators would like to do this by looking up information in your medical record during the year following the scan to see how you are doing. Checking your condition helps us understand whether the \[11C\] acetate PET scan will be helpful to other patients in the future.
FIELD: veterinary science. ^ SUBSTANCE: ligfol preparation is injected intramuscularly to 12-15 month old heifers with serological confirmation of leucosis without clinical signs in two serial 3-month courses. During the first course ligfol is injected once a month in doses of 10.0 ml/head. During the second course ligfol is injected once a month in doses of 15.0 ml/head. ^ EFFECT: method makes it possible to ensure unavailability of transition of asymptomatic stage of leucosis processes into haematological stage, to reduce endogenous intoxication and to increase percentage of segmented neutrophils. ^ 3 tbl, 2 ex
They were isolated with a rubber dam and then a fine-grit, water-cooled diamond bur was applied to the stained and white opaque enamel region for five to 10 seconds to enable penetration of the gel into the enamel. An approximately 1-mm- thick layer of 6.6% hydrochloric acid slurry with silicone carbide microparticles (Opalustre, Ultradent Products Inc, South Jordan, UT, USA) was applied to the affected tooth surfaces.
Community-dwelling older adults will be recruited and placed into one of two groups. Group one will watch a one-time educational video on sleep hygiene and group two will watch the video plus be sent daily automated text messages to reinforce the education learned in the video. The participants will receive the text messages for a total of 4 weeks. The control group will not receive any intervention during this time frame. Following the initial meeting, all participants will wear the sleep tracker on their wrists during the day and night for 4 weeks. The sleep tracker will monitor the physiological markers of sleep provided by wearable technology on sleep efficiency, time in bed, time actually sleeping, and time spent at each stage of sleep. At the end of the 4-week study period, the researchers will once again meet with each participant. The participant will complete the following questionnaires once again.
The development of unstable carotid atherosclerotic plaques is associated with the induction of neutrophil extracellular traps (NETs) via the activation of diverse inflammatory mediators in the circulating bloodstream. However, the underlying mechanisms through which NETs influence the microenvironment of atherosclerotic plaques and contribute to the development of unstable carotid plaques remain largely elusive. The objective of this study was to elucidate the role of myeloid differentiation protein 1 (MD-1, LY86)-induced NETs underlying the crosstalk between unstable plaque formation and the plaque microenvironment. We employed bioinformatics analysis to identify key genes associated with carotid-unstable plaque, followed by comprehensive validation using various experimental approaches on tissue specimens and plasma samples classified based on pathological characteristics. Patients with carotid-unstable plaques exhibited elevated plasma concentrations of MD-1 (LY86), while patients with stable plaques demonstrated comparatively lower levels. Furthermore, soluble MD-1 was found to induce the formation of NETs through activation of Toll-like receptor signaling pathway. The proliferative and immature vascularization effects of NETs on endothelial cells, as well as their inhibitory impact on cell migration, are directly correlated with the concentration of NETs. Additionally, NETs were found to activate the NF-κB signaling pathway, thereby upregulating ICAM1, VCAM1, MMP14, VEGFA, and IL6 expression in both Human umbilical vein endothelial cells (HUVECs) and HAECs. Subsequently, a significant increase in intraplaque neovascularization by NETs results in poor carotid plaque stability, and NETs in turn stimulate macrophages to produce more MD-1, generating a harmful positive feedback loop. Our findings suggest that soluble MD-1 in the bloodstream triggers the production of NETs through activation of the Toll-like receptor signaling pathway and further indicate NETs mediate a crosstalk between the microenvironment of the carotid plaque and the neovascularization of the intraplaque region. Inhibiting NETs formation or MD-1 secretion may represent a promising strategy to effectively suppress the development of unstable carotid plaques.
The present invention provides a sophocarpidine gel preparation. The gel preparation contains 3 to 5% of sophocarpidine and 0.5 to 1.5% of carbomer. The present invention also provides a preparation method of the gel preparation. The preparation method comprises the following steps: the sophocarpidine is extracted with 110 type cation exchange resin; the carbomer used as an auxiliary agent forms gel; the sophocarpidine dissolves in a solution formed by ethanol and propanediol; an obtained mixture is added to the gel; finally, the sophocarpidine gel preparation is obtained. The gel preparation has the advantage of strong adhesive force with mucosa. Accordingly, the residence time of the sophocarpidine in the vagina can be extended, and the therapeutic effect of the sophocarpidine gel preparation can be improved.
Embodiments of the invention include a coating comprising an oligomeric polyphenol layer. The oligomerized polyphenol layer can be used as an intermediate coating layer on a medical device, wherein hydrogen bonding to a synthetic or natural polymer occurs, which in turn can serve as a top coating layer or further associated with another coating layer. The multilayer coating may provide properties such as hemocompatibility or lubricity. In other embodiments, the oligomerized polyphenol layer is used on a medical device as a hemostatic layer configured to contact blood and promote clotting. The oligomerized polyphenol layer can also be applied to the inner surface (e.g., inner diameter) of the medical device to prevent bacterial adhesion. The oligomerized polyphenol layer can also be used on the surface of an in vitro diagnostic article or a cell culture device to promote adhesion of biomolecules.
No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets USP. The following information was obtained from the literature.

Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Adenosine:

Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Cholinesterase Inhibitors:
The invention relates to a system (100) for viewing a first image dataset and a second image dataset, the system (100) comprising a first viewer (120) for computing a first image from the first image dataset, and a second viewer (130) for computing a second image from the second image dataset, wherein the second image is based on the computed first image. The second image, e.g. a reference image computed from the second image dataset, may thus be adapted to show features which can be seen and compared to the features in the first image, e.g. a query image computed from the first image dataset. The system may be further adapted for displaying additional reference images computed from the second image dataset, based on the query image or on new query images selected, for example, by a user of the system. Every time a new query image is computed from the first image dataset, a corresponding reference image is computed from the second image dataset.
Therapeutic compsns contg. either singly or in association lithium pyruvate, dilithium embonate and trilithium phosphate. The compsns are for treatment of manic-depressive psychoses and combine the rapid absorption of the soluble pyruvate with the prolonged activity of the less sol. phosphate and embonate. The oral LD50 for mice is phosphate 3.85 g/kg, embonate 2.35 g/Kg. and pyruvate 4g/kg.
During conventional ventricular arrhythmia ablation procedures, simply contacting the cardiac wall can significantly alter the electrocardiogram. Induction of ventricular ectopy is important in determining the focus of the arrhythmogenic tissue during an electrophysiology (EP) procedure; however, instrumentation with stiff ablation catheters can temporarily eliminate VT during the mapping portion of the procedure making it difficult to track the arrhythmia prior to ablating the tissue responsible for its genesis. The catheters used with the Stereotaxis Magnetic Navigation System (MNS) are less stiff compared to manual catheters since no pull wires are required to deflect the distal tip. Large external magnets positioned on either side of the EP procedure table create a magnetic field within the patient's chest. These large magnets (in direct relationship to the magnetic field) can be manipulated using specialized software. The physician controls the distal tip of the catheter by using the software while remotely using a catheter advancing system (QuickCAS®, Stereotaxis, Inc, St. Louis, MO) to reach the desired location within the heart. The soft catheters may provide a unique quality to the electrophysiologist who may assist by providing accurate maps without temporarily eliminating the ventricular ectopy due to excessive mechanical forces applied to the cardiac tissue. This study will assess the physician's ability to appropriately map and ablate the ventricular substrate using remote magnetic technology. All devices are approved by FDA and no off-label use of the products is mandated within the protocol.
The intricate ecosystem of microorganisms residing within and on the human body, collectively known as the microbiome, significantly influences human health. Imbalances in this microbiome, referred to as dysbiosis, have been associated with various diseases, prompting the exploration of novel therapeutic approaches. Personalized medicine, Tailors treatments to individual patient characteristics, offers a promising avenue for addressing microbiome-related health issues. This review highlights recent developments in utilizing personalized medicine to target the microbiome, aiming to enhance health outcomes. Noteworthy strategies include fecal microbiota transplantation (FMT), where healthy donor microbes are transferred to patients, showing promise in treating conditions such as recurrent Clostridium difficile infection. Additionally, probiotics, which are live microorganisms similar to beneficial gut inhabitants, and prebiotics, non-digestible compounds promoting microbial growth, are emerging as tools to restore microbiome balance. The integration of these approaches, known as synbiotics, enhances microbial colonization and therapeutic effects. Advances in metagenomics and sequencing technologies provide the means to understand individual microbiome profiles, enabling tailored interventions. This paper aims to present the latest insights in leveraging personalized medicine to address microbiome-related health concerns, envisioning a future where microbiome-based therapies reshape disease management and promote human health.
According to inclusion \& exclusion criteria, volunteers will be selected and divided into 4 groups randomly. The clinician who does the injections will not be aware of study purpose. Also the person who does the electric pulp test (EPT); the volunteer and the statistical analyzer will not be aware of group codes. Intervention in each group will be as follow: Group 1-Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine. Group 2-Buccal infiltration of two 4% Articaine cartridges with 1/100000epinephrine. Group 3-Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine. Group 4- Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine. Before injection a control tooth (contralateral canine) will be tested to understand the accuracy of patient's response to EPT; also for measuring the base line vitality, each tooth will be evaluated by EPT twice before injection. After injection each tooth will be evaluated by EPT every 3 minutes; also every minute the anesthesia of lip and tongue will be checked, up to 15 minutes. The tooth will be discerned "anesthetized" if the subject will not response to 80 reading of EPT in 2 consecutive tests. Finally the information will be recorded and in addition to the success rate the mean time for onset of anesthesia and its mean duration time will be evaluated.
Drug-loaded medical devices such as stents and methods for manufacturing them are provided. In certain embodiments, the therapeutic agent is loaded only in or on areas of the medical device that do not undergo substantial deformation during expansion. The medical device may be provided with reservoirs in or on the first portions of the medical device that do not undergo substantial deformation during expansion, and the therapeutic agent may be loaded in these reservoirs. The reservoirs may be covered with a porous coating which may be a non-polymeric coating. In other embodiments, a non-polymeric coating is provided in a discontinuous manner in or on the medical device. A method includes the steps of providing a transfer member that includes a translucent substrate and a layer of transfer material such as a film or foil; attaching reservoirs to the transfer material; positioning the transfer member with the reservoirs adjacent a medical device, such as a stent, with the reservoirs facing the medical device; and directing a laser beam at the transfer member such that the laser beam passes through the translucent substrate to vaporize a portion of the transfer material, creating a pocket of trapped gas between the translucent substrate and reservoir, thereby forcing the reservoir from the transfer member to the medical device. The reservoirs may be formed of a non-polymeric material.
Nivolumab will be administrated intravenously. Standard dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses. The DLT observation period is 29 days starting with the first dose taken on Day 1, The study treatment will continue until one of the discontinuation criteria is met. Each dose level (1-2) will be tested using the 3+3 design. If level 2 of 3mg/kg is reached without DLTs, 3mg/kg will be used for the dose expansion cohort. After the intensification phase, patients will start Nivolumab every 12 weeks maintenance phase till 2 years post allo-SCT. Patients will also receive best supportive care (BSC), including blood product transfusions, antimicrobials, and (as appropriate) granulocyte colony stimulating factors for neutropenic infection or poor graft function.
Patients receive cyclophosphamide IV on day 1, dexamethasone PO on days 1-4, TiNK IV on day 8, and isatuximab IV on days 8 and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy during screening and on study, as well as optionally during follow up. Patients undergo ECHO during screening and blood sample collection throughout the study.
Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) is involved in lipid and glucose metabolism via mRNA processing. However, whether and how HNRNPA1 alters adipocyte function in obesity remain obscure. Here, we found that the obese state downregulated HNRNPA1 expression in white adipose tissue (WAT). The depletion of adipocyte HNRNPA1 promoted markedly increased macrophage infiltration and expression of proinflammatory and fibrosis genes in WAT of obese mice, eventually leading to exacerbated insulin sensitivity, glucose tolerance, and hepatic steatosis. Mechanistically, HNRNPA1 interacted with Ccl2 and regulated its mRNA stability. Intraperitoneal injection of CCL2-CCR2 signaling antagonist improved adipose tissue inflammation and systemic glucose homeostasis. Furthermore, HNRNPA1 expression in human WAT was negatively correlated with BMI, fat percentage, and subcutaneous fat area. Among individuals with 1-year metabolic surgery follow-up, HNRNPA1 expression was positively related to percentage of total weight loss. These findings identify adipocyte HNRNPA1 as a link between adipose tissue inflammation and systemic metabolic homeostasis, which might be a promising therapeutic target for obesity-related disorders.